Abstract
Background: Endothelial Progenitor Cells (EPCs) have been suggested to be a therapeutic option in Acute Ischemic Stroke (AIS). Statins modulate endothelial function and preserve blood flow to tissue exposed to an ischemic insult. We tested the hypothesis that statins therapy might augment circulating EPCs in patients with AIS.
Methods: Demographic data, classical vascular risk factors, treatment and National Institutes of Health Stroke Scale data were prospectively collected from 43 consecutive AIS patients (group I), comprising – 30 treated with statins (group Statin(+)) and 13 untreated (group Statin (-)). Risk factor controls (group II) included 22 subjects matched by age, gender, and traditional vascular risk factors. EPCs were measured by flow cytometry – and the populations of circulating stem cells (CD133+), early EPCs (CD133+/VEGFR2+) and ECs CD34/CD133/VEGFR2+ cells were analyzed.
Results: Patients ages ranged from 54 to 92 years (mean age 75.2 ± 11.3 years). The number of CD34/CD133/VEGF-R2+ cells was significantly lower in group I than II (p<0.05). In group Statin(+) neurological deficit on the 1st, 3rd and 7th day was significantly lower in comparison Statin(-) (p<0.05). We observed significantly more frequent “improvement> 50% or complete recovery” and less frequent death in the statin-treated group. The number of early EPCs and ECs was significantly higher in the treated group on the day 3rd (p < 0.05).
Conclusions: Statins treatment is likely to have a positive effect on spontaneous CD133+/ VEGFR2+ and CD34/CD133/VEGFR2+ cell mobilization triggered by a stroke.
Keywords: Acute ischemic stroke, circulating stem cells (CD133+), early endothelial progenitor cells (CD133+/VEGFR2+), endothelial cells (CD34/CD133/VEGFR2+), statins, angiogenesis.
Current Neurovascular Research
Title:Statins Therapy is Associated with Increased Populations of Early Endothelial Progenitor (CD133+/VEGFR2+) and Endothelial (CD34-/CD133- /VEGFR2+) Cells in Patients with Acute Ischemic Stroke
Volume: 15 Issue: 2
Author(s): Monika Golab-Janowska*, Edyta Paczkowska, Boguslaw Machalinski, Agnieszka Meller, Dariusz Kotlega, Krzysztof Safranow, Pawel Wankowicz and Przemyslaw Nowacki
Affiliation:
- Department of Neurology, Pomeranian Medical University, Szczecin,Poland
Keywords: Acute ischemic stroke, circulating stem cells (CD133+), early endothelial progenitor cells (CD133+/VEGFR2+), endothelial cells (CD34/CD133/VEGFR2+), statins, angiogenesis.
Abstract: Background: Endothelial Progenitor Cells (EPCs) have been suggested to be a therapeutic option in Acute Ischemic Stroke (AIS). Statins modulate endothelial function and preserve blood flow to tissue exposed to an ischemic insult. We tested the hypothesis that statins therapy might augment circulating EPCs in patients with AIS.
Methods: Demographic data, classical vascular risk factors, treatment and National Institutes of Health Stroke Scale data were prospectively collected from 43 consecutive AIS patients (group I), comprising – 30 treated with statins (group Statin(+)) and 13 untreated (group Statin (-)). Risk factor controls (group II) included 22 subjects matched by age, gender, and traditional vascular risk factors. EPCs were measured by flow cytometry – and the populations of circulating stem cells (CD133+), early EPCs (CD133+/VEGFR2+) and ECs CD34/CD133/VEGFR2+ cells were analyzed.
Results: Patients ages ranged from 54 to 92 years (mean age 75.2 ± 11.3 years). The number of CD34/CD133/VEGF-R2+ cells was significantly lower in group I than II (p<0.05). In group Statin(+) neurological deficit on the 1st, 3rd and 7th day was significantly lower in comparison Statin(-) (p<0.05). We observed significantly more frequent “improvement> 50% or complete recovery” and less frequent death in the statin-treated group. The number of early EPCs and ECs was significantly higher in the treated group on the day 3rd (p < 0.05).
Conclusions: Statins treatment is likely to have a positive effect on spontaneous CD133+/ VEGFR2+ and CD34/CD133/VEGFR2+ cell mobilization triggered by a stroke.
Export Options
About this article
Cite this article as:
Golab-Janowska Monika *, Paczkowska Edyta , Machalinski Boguslaw , Meller Agnieszka , Kotlega Dariusz , Safranow Krzysztof , Wankowicz Pawel and Nowacki Przemyslaw , Statins Therapy is Associated with Increased Populations of Early Endothelial Progenitor (CD133+/VEGFR2+) and Endothelial (CD34-/CD133- /VEGFR2+) Cells in Patients with Acute Ischemic Stroke, Current Neurovascular Research 2018; 15 (2) . https://dx.doi.org/10.2174/1567202615666180611120546
DOI https://dx.doi.org/10.2174/1567202615666180611120546 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Imiquimod Increases Cutaneous VEGF Expression in Imiquimod-induced Psoriatic Mouse Model
Current Vascular Pharmacology An Updated Meta-Analysis of the Efficacy and Safety of Acupuncture Treatment for Vascular Cognitive Impairment Without Dementia
Current Neurovascular Research PREFACE: “The Lower the Better” Association between White-coat Effect-excluded Blood Pressure and Cardiovascular Events in High-risk Hypertension: Insights from SPRINT
Current Hypertension Reviews The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
Current Medicinal Chemistry Ghrelin, A Novel Peptide Hormone in the Regulation of Energy Balance and Cardiovascular Function
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Meet Our Editorial Board Member
Current Aging Science Further Vitamin D Analogs
Current Vascular Pharmacology A Double-Toggle Clamping Unit of Injection Molding Machine
Recent Patents on Mechanical Engineering Carvedilol: Just Another Beta-Blocker or a Powerful Cardioprotector?
Cardiovascular & Hematological Disorders-Drug Targets Stem Cells: Clinical Trials Results The End of the Beginning or the Beginning of the End?
Cardiovascular & Hematological Disorders-Drug Targets Arterial Ischemic Stroke in Neonates and Children: Review and Current Issues
Current Pediatric Reviews Motor and Sensory Dysfunction in Musician's Dystonia
Current Neuropharmacology Patent Selections
Recent Patents on Cardiovascular Drug Discovery Clinical Characteristics and Treatment of Cardiomyopathies in Children
Current Cardiology Reviews Repositioning of Drugs in Cardiometabolic Disorders: Importance and Current Scenario
Current Topics in Medicinal Chemistry New Clinical Perspectives of Hypolipidemic Drug Therapy in Severe Hypercholesterolemia
Current Medicinal Chemistry Antisynthetase Syndrome: A Review of Etiopathogenesis, Diagnosis and Management
Current Medicinal Chemistry Stroke Induced Immunodepression Syndrome: From Bench to Bedside
Current Molecular Medicine Brain Peptides for the Treatment of Neuropsychiatric Disorders
Current Pharmaceutical Design Do RAS Inhibitors Protect the Brain from Cerebral Ischemic Injury?
Current Hypertension Reviews